Sign In
Buy ADCT
$1.15
+0.0600 (+5.50%)
At Close: Jun 23, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
10:00am, Thursday, 01'st Jan 2026
NEW YORK, Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC Therapeutics" or the "Company") (NYSE: ADCT). Such investors are adv
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
12:50pm, Tuesday, 30'th Dec 2025
NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC Therapeutics” or the “Company”) (NYSE: ADCT). Such in
ADC Therapeutics (ADCT) Upgraded to Buy: Here's Why
01:00pm, Monday, 29'th Dec 2025
ADC Therapeutics (ADCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year?
10:40am, Wednesday, 17'th Dec 2025
Here is how ADC Therapeutics SA (ADCT) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.
ADC Therapeutics SA (ADCT) is a Great Momentum Stock: Should You Buy?
01:01pm, Monday, 15'th Dec 2025
Does ADC Therapeutics SA (ADCT) have what it takes to be a top stock pick for momentum investors? Let's find out.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
10:00am, Thursday, 11'th Dec 2025
NEW YORK , Dec. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC Therapeutics" or the "Company") (NYSE: ADCT). Such investors are adv
ADC Therapeutics SA (ADCT) Discusses Updated Results From LOTIS-7 Trial Evaluating ZYNLONTA Plus Glofitamab in Relapsed or Refractory DLBCL Transcript
ZYNLONTA® in combination with glofitamab (COLUMVI®) demonstrated an 89.8% ORR and 77.6% CR across the 49 efficacy-evaluable patients with a minimum of 6 months of follow-up Combination continues to
ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial
04:05pm, Tuesday, 02'nd Dec 2025
Company to host corporate webcast to share updated data on December 3, 2025 LAUSANNE, Switzerland , Dec. 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
04:05pm, Monday, 01'st Dec 2025
LAUSANNE, Switzerland , Dec. 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced tha
Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year?
10:41am, Monday, 01'st Dec 2025
Here is how ADC Therapeutics SA (ADCT) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.
ADC Therapeutics (ADCT) Upgraded to Buy: Here's What You Should Know
01:01pm, Tuesday, 18'th Nov 2025
ADC Therapeutics (ADCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ADC Therapeutics SA (ADCT) Q3 2025 Earnings Call Transcript
11:21am, Monday, 10'th Nov 2025
ADC Therapeutics SA ( ADCT ) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants Nicole Riley Ameet Mallik - CEO & Director Mohamed Zaki - Chief Medical Officer Jose Carmona - Chi
ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates
09:42am, Monday, 10'th Nov 2025
ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.42 per share a year ago.
ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update
07:30am, Monday, 10'th Nov 2025
Continued progress across LOTIS-7 with updated data anticipated in 2025 and LOTIS-5 with topline data expected in 1H 2026 Updated data from Phase 2 IIT of ZYNLONTA® plus rituximab in patients with
